Open AccessAnnexin VII as a Novel Marker for Invasive Phenotype of Malignant Melanoma
Author(s) -
Kataoka Tatsuki R.,
Ito Akihiko,
Asada Hideo,
Watabe Kenji,
Nishiyama Kazutaka,
Nakamoto Ken'i,
Itami Satoshi,
Yoshikawa Kunihiko,
Ito Masaki,
Nojima Hiroshi,
Kitamura Yukihiko
Publication year - 2000
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.2000.tb00862.x
Subject(s) - melanoma , annexin , annexin a2 , phenotype , immunohistochemistry , antibody , pathology , annexin a1 , cancer research , metastasis , lymph node , medicine , biology , immunology , cancer , staining , gene , biochemistry
Both F10 and BL6 sublines of B16 mouse melanoma cells are metastatic after intravenous injection, but only BL6 cells are metastatic after subcutaneous injection. While examining the genetic difference between the two sublines, we found a marked reduction of annexin VII expression in BL6 cells. In addition, fusion cell clones of both sublines, were as poorly metastatic as F10 cells after subcutaneous injection, and contained the annexin VII message as abundantly as F10 cells. Hence, we examined whether the annexin VII expression was correlated with the less malignant phenotype of clinical cases by immunohistochemistry. Immunoreactivities to anti‐annexin VII antibody in melanoma cells were evaluated quantitatively by using skin mast cells as an internal positive control. Eighteen patients with malignant melanoma were divided into two groups: lymph node metastasis‐negative and positive groups. The ratio of numbers of patients positive versus negative to the antibody was significantly larger in the former than in the latter group. These results not only indicated that annexin VII serves as a marker for less invasive phenotype of malignant melanoma, but also suggested a possible role of annexin VII in tumor suppression.